Invesaro

Stocks Health care GOVX

NASDAQ · Health care

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. brought in $0 of revenue over the twelve months to June 30, 2026, down 100.0% from a year earlier. It posted a net loss of $20.4M. In fiscal 2025 capital spending exceeded operating cash flow by $21.5M. At June 30, 2026 it held $3.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 27, 2026.

Price
$0.35
-2.58% on the day · September 25, 2026
52-week range $0.35 to $16.80
Market cap
$2.6M
Revenue (last 12 months)
$0
-100.0% year on year

What GeoVax Labs, Inc. does

GeoVax Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GOVX.

Revenue and profit by year

Revenue
FY18: $963.2K $963.2K FY18FY19: $1.2M $1.2M FY19FY20: $1.8M $1.8M FY20FY21: $385.5K $385.5K FY21FY22: $81.5K $81.5K FY22FY23: $0 $0 FY23FY24: $4M $4M FY24FY25: $2.5M $2.5M FY25
Net income
FY18: -$2.6M -$2.6M FY18FY19: -$2.4M -$2.4M FY19FY20: -$3M -$3M FY20FY21: -$18.6M -$18.6M FY21FY22: -$14M -$14M FY22FY23: -$26M -$26M FY23FY24: -$25M -$25M FY24FY25: -$21.5M -$21.5M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$2.5M-$21.6M-$21.5M-$22.40-$21.5M
2024$4M-$25.1M-$25M-$120.46-$24.7M
2023$0-$26.7M-$26M-$357.13-$25.2M
2022$81.5K-$14M-$14M-$309.65-$19.2M
2021$385.5K-$18.7M-$18.6M-$75.97-$11.2M
2020$1.8M-$2.8M-$3M-$53.48-$2.9M

Full financial statements: income, balance sheet and cash flow

A report was expected around September 17, 2026 and is not on file yet.

Estimated from its filing rhythm: about 52 days after its last report of July 27, 2026, its usual gap. Not a date the company has announced. See the report calendar

Where GOVX ranks in Health care

Revenue$2.5M
#537 of 646 in Health care · Bottom 17%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What GeoVax Labs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 17, 2026
  2. September 10, 2026
  3. September 10, 2026
  4. August 31, 2026
  5. August 28, 2026
  6. August 28, 2026
  7. August 14, 2026
  8. August 13, 2026
  9. August 13, 2026
  10. August 10, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 22, 2026. Insider transactions on SEC

Insider trades

What the people running GeoVax Labs, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about GOVX

What does GeoVax Labs, Inc. do?

GeoVax Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GOVX.

Is GeoVax Labs, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $20.4M.

How much revenue does GeoVax Labs, Inc. make?

Over the twelve months to June 30, 2026 GeoVax Labs, Inc. reported revenue of $0. That is 100.0% less than a year earlier.

When did GeoVax Labs, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on July 27, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from September 17, 2026.

Similar companies

Compare GOVX with

Compare GOVX with any company

Follow GOVX

Get an email when GeoVax Labs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow GOVX: get an email when it files

Where the numbers come from

Financial figures are the values GeoVax Labs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.